Home/Pipeline/INV-202 (Buprenorphine LAIN)

INV-202 (Buprenorphine LAIN)

Opioid Use Disorder (OUD)

Phase 3Active

Key Facts

Indication

Opioid Use Disorder (OUD)

Phase

Phase 3

Status

Active

Company

Indivior

About Indivior

Indivior is a publicly traded, revenue-generating biopharmaceutical company dedicated to addressing substance use disorders and serious mental illnesses. A pioneer in addiction medicine, its strategy is anchored by its market-leading SUBLOCADE® (monthly buprenorphine injection) and a pipeline extending its long-acting platform into schizophrenia and depression. The company faces significant risks from ongoing legal liabilities, generic competition, and pipeline execution, but its U.S. relocation, focused commercial execution, and potential new product launches provide a pathway for sustained growth in a critical therapeutic area.

View full company profile

Therapeutic Areas

Substance Use Disorder Opioid Use Disorder Schizophrenia Mental Illness

Other Opioid Use Disorder (OUD) Drugs

Drug	Company	Phase	Status
iSTEP-N	Akyso Therapeutics	Phase 1b	Active
iSTEP-B	Akyso Therapeutics	Pre-clinical	Active
BT-219	Bridge Therapeutics	Pre-clinical	Active